2. Immunology/Inflammation
  3. Complement System
  4. Tanruprubart

Tanruprubart  (Synonyms: ANX005)

Cat. No.: HY-P990545 Purity: 99.047%
COA
SDS
Technical Support

Tanruprubart (ANX005) is a C1q inhibitor and C1q depleter. Tanruprubart is a human antibody expressed in CHO cells, with huIgG1 heavy chains and huκ light chains, and its predicted molecular weight (MW) is 145 kDa. For the isotype control of Tanruprubart, refer to Human IgG1 kappa, Isotype Control (HY-P99001). The IC50 of Tanruprubart is 346 ng/mL for humans and 259 ng/mL for rats; its EC50 is 3.8 ng/mL for humans, 5.2 ng/mL for rats, and 9.9 ng/mL for mice. Tanruprubart is applicable to the research of Guillain-Barré syndrome and Alzheimer's disease.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No. : 2065212-40-8

사이즈 가격 재고 수량
무료 샘플 (100 μg)   지금 신청하기  
1 mg 해외재고보유
5 mg 해외재고보유
10 mg 해외재고보유
50 mg   견적 받기  
100 mg   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

Tanruprubart Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • 순도&문서

  • References

  • 고객리뷰

제품 설명

Tanruprubart (ANX005) is a C1q inhibitor and C1q depleter. Tanruprubart is a human antibody expressed in CHO cells, with huIgG1 heavy chains and huκ light chains, and its predicted molecular weight (MW) is 145 kDa. For the isotype control of Tanruprubart, refer to Human IgG1 kappa, Isotype Control (HY-P99001). The IC50 of Tanruprubart is 346 ng/mL for humans and 259 ng/mL for rats; its EC50 is 3.8 ng/mL for humans, 5.2 ng/mL for rats, and 9.9 ng/mL for mice. Tanruprubart is applicable to the research of Guillain-Barré syndrome and Alzheimer's disease[1].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

C1q
In Vitro

Tanruprubart (ANX005) (Titered concentrations) binds with high, comparable affinity to serum-derived C1q from human, cynomolgus monkey, rhesus monkey, dog, and rat, has lower affinity for mouse C1q, and does not bind rabbit C1q[1].
Tanruprubart (Titered concentrations; 1 h) potently inhibits classical complement-mediated hemolysis in human, cynomolgus monkey, rhesus monkey, dog, and rat serum, with an average IC50 of ~350 ng/mL, and does not inhibit hemolysis in rabbit serum[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tanruprubart Related Antibodies
In Vivo

Tanruprubart (ANX005) (10-200 mg/kg; i.v.; once weekly; 4 weeks) administered to Sprague Dawley rats for 4 weeks produces dose-dependent serum and CSF exposures, fully depletes free serum C1q at measurable reagent levels, and shows no treatment-related toxicity at doses up to 200 mg/kg, resulting in a no observed adverse effect level (NOAEL) of 200 mg/kg[1].
Tanruprubart (ANX005) (10-200 mg/kg; i.v.; single bolus dose; once weekly; 4 weeks) administered to cynomolgus monkeys (as single doses or weekly doses for 4 weeks) produces dose-dependent serum and CSF exposures, fully depletes free serum C1q and inhibits complement-mediated hemolysis at measurable reagent levels, fully occupies CSF C1q at higher doses, and shows no treatment-related toxicity at doses up to 200 mg/kg, resulting in a no observed adverse effect level (NOAEL) of 100 mg/kg[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague Dawley rats (male and female, young adult, 8-9 weeks old)[1]
Dosage: 10 mg/kg; 50 mg/kg; 100 mg/kg; 200 mg/kg
Administration: i.v.; once weekly; 4 weeks
Result: Depleted free C1q in rat serum at measurable reagent levels.\nShowed dose-proportional increases in serum Cmax; AUC increased greater than dose-proportionally between lower doses, and dose-proportionally between 100 and 200 mg/kg.\nIncreased mean CSF concentrations in a greater-than-dose-proportional manner, with CSF levels representing 0.1% to 0.2% of serum levels on days 38 and 50 of the GLP study.\nExhibited no treatment-related changes in clinical signs, body weight, food consumption, clinical pathology, gross pathology, organ weight, or histopathology at any dose tested.\nAchieved a no observed adverse effect level (NOAEL) of 200 mg/kg.
Animal Model: Cynomolgus monkeys (male and female, 2-4 years old)[1]
Dosage: 15 mg/kg (single bolus); 100 mg/kg (single bolus); 10 mg/kg (weekly x4); 50 mg/kg (weekly x4); 100 mg/kg (weekly x4); 200 mg/kg (weekly x4)
Administration: i.v.; single bolus dose; once weekly; 4 weeks
Result: Depleted free C1q in monkey serum at measurable reagent levels, with free C1q returning to baseline only when reagent levels dropped below detection.\nInhibited ex vivo complement-mediated hemolysis completely at measurable reagent serum levels, with hemolysis activity returning to baseline when reagent levels declined.\nShowed dose-dependent increases in serum concentrations, with trough levels accumulating over weekly doses in the 50, 100, and 200 mg/kg groups (excluding animals with anti-drug antibody responses).\nIncreased mean CSF concentrations with dose, with CSF levels representing 0.04% to 0.11% of serum levels in the non-GLP study, and 0.02% to 0.13% of serum levels in the GLP study on day 29; these CSF levels fully occupied C1q in the CSF at 100 and 200 mg/kg doses on day 29.\nExhibited no treatment-related changes in clinical signs, body weight, food consumption, clinical pathology, gross pathology, organ weight, histopathology, ophthalmic findings, neurologic exams, vital signs, or electrocardiograms at any dose tested.\nAchieved a no observed adverse effect level (NOAEL) of 200 mg/kg.
Gene ID

712  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
분자량

145.78 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

선적

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
  • Immobilized C1q Protein (HY-NP0194) can bind ANX005. The EC50 for this effect is 2.56 ng/mL.
순도&문서

Purity: 99.047%

SDS (251 KB)

COA (232 KB) SDS-PAGE (64 KB) SEC-HPLC (158 KB)

Inhibitory Antibodies User Guide (603 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tanruprubart Related Classifications

  • 몰농도 계산기

  • 농도 희석 계산기

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tanruprubart2065212-40-8ANX005ANX 005ANX-005Complement Systemcynomolgus monkeyclassical complement pathwayratdogC1qmouseblood-brain barrierrhesus monkeyGuillain-Barré syndromeclassical complement cascadeInhibitorinhibitorinhibit

최근 본 상품:

온라인 문의

Your information is safe with us. * Required Fields.

상품명

  

Requested Quantity *

고객명 *

 

호칭

메일주소 *

 

전화번호 *

Department

 

회사명 *

City

도

Country or Region *

      

비고

대량구매 문의

Inquiry Information

상품명:
Tanruprubart
Cat. No.:
HY-P990545
수량:
MCE Japan Authorized Agent:

고객리뷰

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

상품명

  

Lot #

고객명 *

 

메일주소 *

전화번호

 

Department *

회사명 *

 

Country or Region *

비고

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.